- Home
- DEA vs IOVA Comparison
DEA vs IOVA Comparison
Compare DEA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | IOVA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.2M | 968.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | DEA | IOVA |
|---|---|---|
| Price | $21.44 | $2.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $24.99 | $10.45 |
| AVG Volume (30 Days) | 590.6K | ★ 11.3M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $334,212,000.00 | $250,425,000.00 |
| Revenue This Year | $9.72 | $60.94 |
| Revenue Next Year | $8.67 | $60.85 |
| P/E Ratio | $72.13 | ★ N/A |
| Revenue Growth | 10.62 | ★ 175.62 |
| 52 Week Low | $19.33 | $1.64 |
| 52 Week High | $29.74 | $8.15 |
Technical Indicators
Market Signals| Indicator | DEA | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 58.51 |
| Support Level | $21.81 | $2.08 |
| Resistance Level | $22.59 | $2.60 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 13.48 | 77.88 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.